SCHEMBL6772228

SCHEMBL6772228

CCOC(=O)CC(NC(=O)CNC(=O)c1cccc(NC(=O)Nc2ccccc2)c1)c1cccnc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR139 Q6DWJ6 3/20 0.43
ROCK2 O75116 2/20 0.43
ALDH1A1 P00352 2/20 0.43
HTT P42858 1/20 0.43
CYP3A4 P08684 1/20 0.42
CYP3A5 P20815 1/20 0.42
SUCNR1 Q9BXA5 2/20 0.42
MAPK14 Q16539 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ITGB3 P05106 2/20 0.42
ITGA2B P08514 2/20 0.42
MAPT P10636 1/20 0.41
NAMPT P43490 1/20 0.41
NPC1 O15118 1/20 0.41
HPGD P15428 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
EPHX2 P34913 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7345147 0.94 ROCK2 (0.41) GPR139ROCK2ALDH1A1SUCNR1MEN1
SCHEMBL7347786 0.94 GPR139 (0.49) GPR139ROCK2ALDH1A1MEN1KMT2A
SCHEMBL6779485 0.93 NAMPT (0.50) ROCK2MAPK14KMT2AITGB3MAPT
SCHEMBL7338807 0.92 ROCK2 (0.45) GPR139ROCK2ALDH1A1SUCNR1MEN1
SCHEMBL7832728 0.92 ROCK2 (0.42) GPR139ROCK2ALDH1A1SUCNR1MEN1
SCHEMBL7347790 0.92 LMNA (0.45) ROCK2MEN1KMT2AITGB3MAPT
SCHEMBL7339949 0.91 ROCK2 (0.44) GPR139ROCK2ALDH1A1SUCNR1ITGB3
SCHEMBL7836891 0.90 NAMPT (0.56) ROCK2KMT2AITGB3NAMPTSMN1; SMN2
SCHEMBL7835665 0.89 ITGB3 (0.45) GPR139ROCK2ALDH1A1SUCNR1ITGB3
SCHEMBL6773670 0.89 ROCK2 (0.43) GPR139ROCK2ALDH1A1SUCNR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed